Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

63%

5 trials in Phase 3/4

Results Transparency

63%

5 of 8 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 3
5(62.5%)
Phase 2
3(37.5%)
8Total
Phase 3(5)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT06979544Phase 3Completed

A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD

Role: lead

NCT04685993Phase 2Completed

A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial

Role: lead

NCT04874350Phase 2Completed

A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia

Role: lead

NCT04134091Phase 2Completed

The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis

Role: lead

NCT03868059Phase 3Completed

Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men

Role: lead

NCT03242590Phase 3Completed

Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).

Role: lead

NCT03242408Phase 3Completed

Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021)

Role: lead

NCT02081300Phase 3Completed

Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism

Role: lead

All 8 trials loaded